July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Optic nerve head and macula perfusion in diabetics after anti-VEGF injection
Author Affiliations & Notes
  • Katherine Makedonsky
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Charles Wu
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Mary K Durbin
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Subhransu Ray
    Bay Area Retina Associates, California, United States
  • Footnotes
    Commercial Relationships   Katherine Makedonsky, Carl Zeiss Meditec, Inc. (E); Charles Wu, Carl Zeiss Meditec, Inc. (C); Mary Durbin, Carl Zeiss Meditec, Inc. (E); Subhransu Ray, Carl Zeiss Meditec, Inc. (C), Santen Pharmaceutical (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3076. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katherine Makedonsky, Charles Wu, Mary K Durbin, Subhransu Ray; Optic nerve head and macula perfusion in diabetics after anti-VEGF injection. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3076.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Glaucoma studies have shown that patients with elevated intraocular pressure (IOP) have poor optic nerve perfusion. Furthermore, an increase in IOP immediately after intravitreal anti-VEGF injection can result in a transient decrease of mean ocular perfusion pressure [Lee BMC 2016]. The purpose of this study is to quantify the perfusion of the optic nerve and macula in response to Anti-VEGF injection in diabetics using OCT angiography.

Methods : Optic Nerve (ONH) 4.5x4.5 mm and macula 3x3 mm angiography scans were obtained using CIRRUS™ HD-OCT 5000 with AngioPlex® OCT Angiography (ZEISS, Dublin, CA) on a diabetics receiving anti-VEGF as part of clinical care. Prior to injection, Tono-Pen AVIA®( Reichert Technologies, Depew, NY) was used to measure baseline IOP. Post injection, IOP, ONH scan and macula scan were performed at 1, 10, and 20 minutes. Angiography metrics were calculated at each time point with CIRRUS 11.0 software. ONH perfusion was calculated based on the vasculature network between internal limiting membrane (ILM) and retinal nerve fiber layer. Macular perfusion was calculated based on the vasculature network between ILM and outer boundary of inner plexiform layer. For each diabetic, scans from a normal subject with age within 5 years were retrospectively identified and evaluated for comparison.

Results : Figure 1 shows macular and optic nerve perfusion of normal and diseased patients. At baseline, the macular perfusion of 8 diabetics (Age: 57 +/- 11) was significantly less perfused (p=0.01) than 8 normals (Age: 53 +/- 10) while the perfusion at the optic nerve was similar (p=0.16) to 8 normals (Age: 55 +/- 10). Post injection, IOP increased (p=0.002) and optic nerve head perfusion decreased (p=0.045). Macular perfusion post-injection decreased insignificantly (p=0.10). Figure 2 shows IOP and ONH perfusion changes.

Conclusions : Diabetics have a less perfused macula, but a normally perfused optic nerve compared to normals at baseline. IOP increased in all patients post-injection while optic nerve perfusion decreased in 6 out of 8 patients. Macular perfusion did not show a specific trend. However, after 20 minutes, measured parameters tended to return to baseline. AngioPlex OCTA demonstrates the transient effect on optic nerve perfusion expected in response to IOP increase due to intravitreal injection.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Macula and ONH perfusion in normal and diseased

Macula and ONH perfusion in normal and diseased

 

IOP and ONH perfusion at baseline and post-injection

IOP and ONH perfusion at baseline and post-injection

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×